Webpackaging logo

Aptar Pharma Acquires Worldwide License for Orbital™ High Payload Dry Powder Inhaler

  • Aptar Pharma
Health, Pharmaceuticals, Oral Inhalers

Aptar Pharma, a global leader in drug delivery and active material science solutions and services, today announced that it has acquired the worldwide rights to clinical stage drug developer Pharmaxis’ proprietary Orbital™ inhaler, a unique device designed to deliver high payload dry powder to the lungs.

The Orbital technology helps meet an increasing global need to deliver high doses of drugs, such as antibiotics, to the lungs and allows powder payloads of up to 400mg to be inhaled by patients in divided doses without the need to reload. This unique platform was originally developed as a life cycle extending product for the Pharmaxis cystic fibrosis drug Bronchitol® (mannitol).

Howard Burnett, Vice President Global Pulmonary Category, Aptar Pharma commented,

“With this acquisition, Aptar Pharma is pleased to be building on our current expertise for the treatment of chronic conditions. As a recognized global leader in respiratory drug delivery devices and associated services, we now have a wider offering to meet our customer needs.”

Gary Phillips, CEO Pharmaxis added, “I am delighted that Aptar Pharma, who are one of the world’s foremost drug delivery device companies, have seen the potential in the Orbital technology. We look forward to them building on the technical evaluations carried out during the option period and delivering new product solutions that can benefit drug developers and patients. Today’s announcement is a further example of our strategy to generate non-dilutive cash from the mannitol respiratory business.”

This acquisition strengthens Aptar Pharma’s leadership in respiratory by offering a broader range of devices and services, from formulation to patient. Coupled with their formulation expertise at Nanopharm, Human Factors and patient onboarding at Noble, analytical services at Next Breath – all Aptar Pharma companies - as well as their Digital Health offering, Aptar Pharma is able to optimize device design, customize drug development and differentiate with improved compliance to provide their customers with a value-added finished product.

See also

New FDA approved combination product with Aptar Pharma's VP3 nasal spray system

Aptar Pharma, a global leader in drug delivery systems, services and active material science solutions, today announced that its VP3 multidose device is the delivery system for Glenmark’s Ryaltris™ nasal spray, which recently received New Drug Application (NDA) approval by the U.S. Food and Drug Administration. New FDA approved combination product for seasonal allergic rhinitis symptoms with Aptar Pharma's VP3 nasal spray system

Aptar Pharma granted exclusive license option by Pharmaxis to develop and promote high payload dry powder inhaler

Aptar Pharma have entered into an agreement with Pharmaxis, a clinical stage drug developer, under which Aptar Pharma has the option to acquire the worldwide rights to Pharmaxis’ proprietary high payload dry powder inhaler, Orbital. As part of the agreement, Aptar Pharma will evaluate the commercial applications for the Orbital device and further develop the prototype device to meet unmet market needs. Pharmaxis retains the rights to devices containing Orbital intellectual property used to deliver inhaled mannitol.

Noble and Aptar Pharma launch AdhereIT, a connected medical device solution for disease management adherence and onboarding patients

Noble and Aptar Pharma are pleased to announce the launch of AdhereIT - a connected, intuitive and user-friendly onboarding solution for the growing number of patients with chronic conditions who use autoinjectors to administer their medications at home. AdhereIT is the first fully interchangeable, connected add-on solution that can work across a multitude of autoinjector platforms.

Aptar Seeks FDA Emergency Use Authorization for Decontaminating N95 Masks with ActivShield

AptarGroup, Inc. is seeking U.S. FDA Emergency Use Authorization (EUA) for a solution that allows easy disinfecting of N95 filtering facepiece respirators (N95 masks) using their ActivShieldTM. The N95 masks are desperately needed by healthcare personnel due to the shortage of disposable masks during the COVID-19 pandemic and this simple disinfecting process lets medical professionals reuse the masks after decontaminition.

Aptar Pharma’s Nasal Unidose Device approved by US FDA for new nasal seizure rescue treatment

Aptar Pharma has announced that its patented Unidose Liquid System is the device delivering a new nasal spray approved by the U.S. FDA as a rescue treatment for people with epilepsy aged six and older suffering from acute repetitive seizures. Aptar’s Unidose Liquid System is a single-use, ready-to-use one-step nasal delivery device which can deliver a formulation in an emergency situation quickly and easily.

Aptar Pharma’s preservative-free multidose dispenser approved in the US for Allergan’s REFRESH RELIEVA PF artificial tear formulation

Aptar Pharma has announced that its innovative, preservative-free multidose Ophthalmic Squeeze Dispenser is the delivery system for Allergan’s REFRESH RELIEVA PF, its new over-the-counter (OTC) preservative-free treatment for eye dryness in the U.S. This use reconfirms the market-leading position of Aptar Pharma’s Ophthalmic Squeeze Dispenser as the multidose delivery system for ophthalmic agents and formulations without preservatives.

Aptar’s Nasal Unidose Device approved by US FDA

AptarGroup, Inc, a global leader in dispensing and drug delivery solutions, has announced that its Unidose Powder System was recently approved by the U.S. Food and Drug Administration (FDA) for an intranasal, needle-free rescue treatment drug intended to treat severe hypoglycemia in people with diabetes. This marks the first FDA approval of a prescription drug using Aptar’s patented Unidose Powder System and is Aptar’s first combination of a drug delivery device with a protective active packaging container.

Aptar acquires Nanopharm and Gateway Analytical, broadening pharma services platform to accelerate customer drug development

AptarGroup, Inc. has announced that it has acquired two leading pharmaceutical services companies, Nanopharm Ltd. and Gateway Analytical LLC, for a combined enterprise value of approximately $50 million. The acquisitions are part of Aptar’s strategy to broaden its portfolio of services that support pharmaceutical and biotech customers to accelerate and derisk their complex product developments.

Aptar Pharma's Freepod nasal spray device with GlaxoSmithKline's Otrivin wins prestigious WPO WorldStar 2019 award

Aptar Pharma, a leading provider of innovative drug delivery systems, has announced that its patented Freepod nasal spray device with GlaxoSmithKline's Otrivin has received a Medical & Pharma category award at the World Packaging Organization (WPO) 2019 WorldStar Packaging Awards ceremony, which took place on May 15, 2019 in Prague. The WorldStar Awards Competition, hosted by the WPO, is considered to be one of the most prestigious international packaging awards events.

  • Company News
  • English
  • Modified 08 Aug 2022
  • Hits 198